Extended-spectrum β-lactamases in multidrug-resistant Escherichia coli: Changing the therapy for hospital-acquired and community-acquired infections

Clinical Infectious Diseases

Volumn 43, Issue 11, 2006, Pages 1415-1416

  Helfand, Marion S ^a   Bonomo, Robert A ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; BILE DUCT OBSTRUCTION; COMORBIDITY; DISEASE PREDISPOSITION; ESCHERICHIA COLI; GERIATRIC PATIENT; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; INTRAVENOUS CATHETER; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; NOTE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE CATHETER;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS;

EID: 33751572498     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/508891     Document Type: Note

References (11)

1. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennet JE. Dolin R, eds. Principles and practice of infectious diseases. Vol. I. 6th ed. Philadelphia: Churchill Livingston, 2005:773-805.
2. Rodríguez-Baño J, Navarro MD, Romero L, et al. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006;43:1407-14 (in this issue).
3. Chen Y, Delmas J, Sirot J, Shoichet B, Bonnet R. Atomic resolution structures of CTX-M beta-lactamases: extended spectrum activities from increased mobility and decreased stability. J Mol Biol 2005;348:349-62.
4. Morosini MI, Garcia-Castillo M, Coque TM, et al. Antibiotic coresistance in extended-spectrum-beta-lactnniase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006; 50:2695-9.
5. Karisik E, Ellington MJ, Pike R, Warren RE, Livermore DM, Woodford N. Molecular characterization of plasmids encoding CTX-M-15 beta-lactamases from Escherichia coli strains in the United Kingdom. J Antimicrob Chemother 2006;58:665-8.
6. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56:52-9.
7. Calbo E, Romani V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006; 57:780-3.
8. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-74.
9. Grayson ML. The treatment triangle for staphylococcal infections. N Engl J Med 2006; 355:724-7.
10. Ellington MJ, Livermore DM, Pitt TL, Hall LM, Woodford N. Mutators among CTX-M β-lactamase-producing Esherichia coli and risk for the emergence of fosfomycin resistance. J Antimicrob Chemother 2006; 58:848-52.
11. Helfand MS, Bonomo RA. Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum beta-lactamases and metallo-beta-lactamases on the treatment of resistant gram-negative pathogens. Curr Opin Pharmacol 2005; 5:452-8.